Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorFirst Affiliated Hospital, Sun Yat-Sen University

About this trial

This multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells (EpiSCs) for repairing difficult-to-heal wounds. Eligible patients are randomized to receive either: (1) the experimental intervention (rapidly constructed EpiSCs-loaded scaffold combined with split-thickness skin graft via one-step or two-step procedure), or (2) control intervention (acellular scaffold combined with split-thickness skin graft). The primary outcome is the complete wound healing rate at 4 weeks post-surgery. Secondary outcomes include wound recurrence, scar quality (VSS/POSAS), functional recovery (sweat test), mortality, amputation rate, and safety profile.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All-age population

Disqualifiers

History of allergy to allogeneic/xenogeneic tissue-engineered scaffolds or collagen materials

Trial design

Design model

Parallel

Treatments tested in this trial

  • Rapid Tissue-Engineered Skin

    Procedure/Surgery

    Autologous split-thickness skin (0.15-0.2 mm) is harvested from the donor site at a donor-to-wound area ratio of 1:20-30. The harvested skin is processed using a specialized cell sorter to isolate autologous epidermal stem cells (EpiSCs) with \>93% viability within 30 minutes. The cell suspension is adjusted to a concentration of ≥1×10⁶ cells/mL and loaded onto a tissue-engineered scaffold via spraying or immersion (3-5 minutes). The cell-seeded scaffold is then applied to the wound bed. Depending on wound condition: (1) One-step procedure: scaffold and a split-thickness skin graft (0.15-0.2 mm) are applied simultaneously; (2) Two-step procedure: scaffold is implanted first, followed by split-thickness skin graft at 14±3 days post-primary surgery. Negative pressure wound therapy (-100 to -125 mmHg) is applied as needed.

  • Traditional Composite Skin Graft

    Procedure/Surgery

    The same tissue-engineered scaffold (without cell loading) is used. Autologous split-thickness skin graft (0.15-0.2 mm thickness) is harvested. The acellular scaffold is applied to the debrided wound bed followed by coverage with the split-thickness skin graft. The surgical procedure, postoperative wound care, negative pressure wound therapy (-100 to -125 mmHg when indicated), and follow-up protocol are identical to those in the experimental arm. This comparator represents the current standard of care for composite skin grafting in the participating centers.

Treatment groups

1,000 Participants
are divided into 2 treatment groups
Group A: Rapid Tissue-Engineered Skin GroupExperimental treatment 1 intervention
Group B: Traditional Composite Skin Graft GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Complete Wound Healing Rate

The percentage of participants achieving complete wound epithelialization (defined as 100% re-epithelialization without drainage or dressing requirements)

Time frame
At 4 weeks post-surgery

Secondary outcomes

1

Wound Recurrence Rate

Incidence of wound recurrence at the healed site

Time frame
3, 6, 12 months post-surgery
2

Scar Quality Assessment

Scar quality is assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at 4 weeks, 3, 6, and 12 months post-surgery. The VSS total score ranges from 0 to 13, with higher scores indicating worse scar outcome (assessing vascularity, pigmentation, pliability, and height). The POSAS includes two separate subscales: the Observer Scale (6 items, each scored 1 to 10, total range 6-60) and the Patient Scale (6 items, each scored 1 to 10, total range 6-60). For both POSAS subscales, higher scores represent worse scar outcome.

Time frame
4 weeks, 3, 6, 12 months post-surgery
3

Functional Recovery

Sweat test for assessment of sweat gland regeneration

Time frame
6, 12 months post-surgery
4

Mortality Rate

All-cause mortality

Time frame
3, 6, 12 months post-surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.